
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Cytovation ASA raises US$8m in Series A
A Series A follow-up financing of US$8m has brought up Cytovation ASA’s total Series A funding to US$28m. The Bergen-based company announced it will...

Vitestro raises €12m in Series A financing
California-based Sonder Capital led the Series A financing round alongside existing investors and new private investors. According to...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

VectivBio taken over in $1bn acquisition
VectivBio Holding AG has entered into a acquisition agreement with Ironwood Pharmaceuticals Inc. Ironwood will launch a tender offer to buy...

Wacker AG expands biotech business through €100m acquisition
Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The...